Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs T-Rex 2X Long MSTR Daily Target ETF (MSTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs T-Rex 2X Long MSTR Daily Target ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.89 (market cap $8.04B), while T-Rex 2X Long MSTR Daily Target ETF trades at $2.02. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| BIO | MSTU | |
|---|---|---|
Market Cap | $8.04B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $339.75 | $106.80 |
52-Week Low | $241.71 | $1.46 |
Enterprise Value | $7.85B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
MSTU (T-REX 2X Long MSTR Daily Target ETF) trades at $1.78, down 5.07% today amid significant bearish technical signals. The leveraged ETF tracking MicroStrategy has experienced extreme volatility, with news reports indicating a 95% decline over the past year. Technical indicators show overwhelming bearish momentum with moving averages unanimously negative, while fundamental data remains unavailable for this specialized leveraged product.
The outlook remains highly speculative given the ETF's leveraged structure and dependence on MicroStrategy's Bitcoin-heavy strategy. Investment opportunity exists only for sophisticated traders comfortable with extreme volatility, while risks include daily rebalancing decay, concentration in a single stock, and amplified losses during market downturns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →
